399 related articles for article (PubMed ID: 32619764)
21. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.
Helleberg M; Niemann CU; Moestrup KS; Kirk O; Lebech AM; Lane C; Lundgren J
J Infect Dis; 2020 Sep; 222(7):1103-1107. PubMed ID: 32702095
[TBL] [Abstract][Full Text] [Related]
22. Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
Thalha AMM; Lee YY; Besari A; Omar SFS
J R Coll Physicians Edinb; 2020 Jun; 50(2):159-161. PubMed ID: 32568289
[No Abstract] [Full Text] [Related]
23. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia: A case report.
Gonzales-Zamora JA; Quiroz T; Vega AD
Medwave; 2020 Aug; 20(7):e7998. PubMed ID: 32876623
[TBL] [Abstract][Full Text] [Related]
25. Use of remdesivir for patients with Covid-19: a review article.
Azevedo TCP; Azevedo PCP; Silveira Filho RN; Carvalho ARVS; Cezarotti Filho ML; Barbosa FT; Sousa-Rodrigues CF; Matos-Rocha TJ; Ramos FWDS
Rev Assoc Med Bras (1992); 2020 Jun; 66(6):838-841. PubMed ID: 32696862
[TBL] [Abstract][Full Text] [Related]
26. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
27. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
28. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Goldman JD; Lye DCB; Hui DS; Marks KM; Bruno R; Montejano R; Spinner CD; Galli M; Ahn MY; Nahass RG; Chen YS; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wei X; Gaggar A; Brainard DM; Towner WJ; Muñoz J; Mullane KM; Marty FM; Tashima KT; Diaz G; Subramanian A;
N Engl J Med; 2020 Nov; 383(19):1827-1837. PubMed ID: 32459919
[TBL] [Abstract][Full Text] [Related]
29. Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis.
Shih WJ; Yao C; Xie T
Ther Innov Regul Sci; 2020 Sep; 54(5):1236-1255. PubMed ID: 32865809
[TBL] [Abstract][Full Text] [Related]
30. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
Sun D
AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
[TBL] [Abstract][Full Text] [Related]
31. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Andreou A; Trantza S; Filippou D; Sipsas N; Tsiodras S
In Vivo; 2020 Jun; 34(3 Suppl):1567-1588. PubMed ID: 32503814
[TBL] [Abstract][Full Text] [Related]
32. Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.
Dobrovolny HM
Virology; 2020 Nov; 550():61-69. PubMed ID: 32882638
[TBL] [Abstract][Full Text] [Related]
33. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
Jorgensen SCJ; Kebriaei R; Dresser LD
Pharmacotherapy; 2020 Jul; 40(7):659-671. PubMed ID: 32446287
[TBL] [Abstract][Full Text] [Related]
34. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.
Musa A; Pendi K; Hashemi A; Warbasse E; Kouyoumjian S; Yousif J; Blodget E; Stevens S; Aly B; Baron DA
West J Emerg Med; 2020 May; 21(4):737-741. PubMed ID: 32726230
[TBL] [Abstract][Full Text] [Related]
35. A Review of Remdesivir for COVID-19: Data to Date.
Mehta M; Shyh GI
Cardiol Rev; 2020; 28(6):332-334. PubMed ID: 32773440
[TBL] [Abstract][Full Text] [Related]
36. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement.
Paladugu S; Donato AA
Ann Intern Med; 2020 Jul; 173(2):JC4. PubMed ID: 32687756
[TBL] [Abstract][Full Text] [Related]
37. Missed Opportunities on Emergency Remdesivir Use.
Sarpatwari A; Kaltenboeck A; Kesselheim AS
JAMA; 2020 Jul; 324(4):331-332. PubMed ID: 32579163
[No Abstract] [Full Text] [Related]
38. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2020; 14(4):641-648. PubMed ID: 32428865
[TBL] [Abstract][Full Text] [Related]
39. Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2).
Maveddat A; Mallah H; Rao S; Ali K; Sherali S; Nugent K
Int J Occup Environ Med; 2020 Oct; 11(4):157-178. PubMed ID: 33098401
[TBL] [Abstract][Full Text] [Related]
40. Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City.
Chao JY; Derespina KR; Herold BC; Goldman DL; Aldrich M; Weingarten J; Ushay HM; Cabana MD; Medar SS
J Pediatr; 2020 Aug; 223():14-19.e2. PubMed ID: 32407719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]